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Abstract
Genomic changes affecting tumour suppressor genes are fundamental to cancer. We applied SNP array analysis
to a panel of testicular germ cell tumours to search for novel tumour suppressor genes and identified a frequent
small deletion on 6q25.3 affecting just one gene, ZDHHC14. The expression of ZDHHC14, a putative protein
palmitoyltransferase with unknown cellular function, was decreased at both RNA and protein levels in testicular
germ cell tumours. ZDHHC14 expression was also significantly decreased in a panel of prostate cancer samples
and cell lines. In addition to our findings of genetic and protein expression changes in clinical samples, inducible
overexpression of ZDHHC14 led to reduced cell viability and increased apoptosis through the classic caspase-
dependent apoptotic pathway and heterozygous knockout of ZDHHC14 decreased cell colony formation ability.
Finally, we confirmed our in vitro findings of the tumour suppressor role of ZDHHC14 in a mouse xenograft
model, showing that overexpression of ZDHHC14 inhibits tumourigenesis. Thus, we have identified a novel tumour
suppressor gene that is commonly down-regulated in testicular germ cell tumours and prostate cancer, as well as
given insight into the cellular functional role of ZDHHC14, a potential protein palmitoyltransferase that may play
a key protective role in cancer.
 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great
Britain and Ireland.
Keywords: ZDHHC14; tumour suppressor gene; testicular germ cell tumours; prostate cancer; apoptosis
Received 9 August 2013; Revised 20 December 2013; Accepted 3 January 2014
No conflicts of interest were declared.
Introduction
Tumourigenesis is a multistep process in which, elicited
by the activation of oncogenes and the inactivation of
tumour suppressor genes (TSGs), cells acquire increas-
ingly malignant characteristics. TSGs prevent tumour
initiation and progression by acting in signalling net-
works that regulate cell proliferation, differentiation,
apoptosis, and other cellular and systemic processes.
TSGs can be inactivated by deletions, point mutations
[1] or by epigenetic mechanisms such as DNA methy-
lation and histone modifications [2]. Among them,
deletion is one of the most frequent genetic alter-
ations detected in cancer cells and recurrent dele-
tions detected in certain regions have been widely
interrogated to identify TSGs. The development of
comparative genomic hybridization and DNA microar-
ray technologies has made it easy to identify genomic
copy number alterations and has accelerated the discov-
ery of TSGs. Single nucleotide polymorphism (SNP)
arrays allow the determination of both genomic copy
number changes and loss of heterozygosity (LOH),
including copy number neutral LOH [3,4]. Many novel
TSGs have been discovered in human malignancies
using SNP array analysis, including PAX5 as a key
target of genetic inactivation in B-cell acute lympho-
cytic leukaemia [5], PTPRD as a tumour suppressor
in lung cancer and glioma [6,7], and IKFZF1 in acute
lymphoblastic leukaemia [8].
Testicular germ cell tumours (TGCTs) are the most
common malignancy in young men. Many genetic
studies have been carried out in TGCTs and the
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characteristic genetic change, gain of 12p [9], has been
identified. Previous low-resolution genetic studies of
TGCTs identified more genomic copy number gains
rather than losses [9]. Interestingly, deregulation of
important tumour suppressor genes such as RB1 , TP53 ,
APC , WT1 , MCC , and BRCA1 is rare in this type of
cancer [10–12]. However, few array-based genome-
wide studies have been performed for TGCTs. Using
the Affymetrix 10 K SNP array, we analysed a series of
TGCTs to identify genome-wide copy number changes,
in particular frequently occurring small genomic region
gains and losses. We found frequent deletion of a
small genomic region within 6q25.3 affecting only
one known gene, ZDHHC14 . Further genetic studies
revealed additional genomic alterations and reduced
expression of ZDHHC14 not only in TGCTs, but
also in prostate cancer. Using cell-based assays and
xenografts, we performed functional studies that iden-
tified ZDHHC14 as a novel tumour suppressor.
Materials and methods
Cell lines
Three human TGCT cell lines, 833 K, Susa, and
GCT27 (obtained from Jennifer Parrington, John Mas-
ters, and Lloyd Kelland, respectively), five human
prostate cancer cell lines, PC-3, DU-145, LNCaP,
VCaP, and 22RV1 (ATCC, Manassas, VA, USA), and
one immortalized human prostate epithelial cell line,
PNT2-C2 (obtained from Norman Maitland), and the
human embryonic kidney HEK293 (ATCC) and T-
RExTM 293 (Invitrogen, Carlsbad, CA, USA) cell lines
were used in this study. All cell lines were verified by
STR profiling using the ABI AmpF/STR Identifiler kit
(Applied Biosystems, Foster City, CA, USA).
Clinical samples
Fresh frozen TGCT and prostate cancer samples
were collected and stored in ethically approved tissue
banks, and used in this study under local ethics
committee approval. Archived paraffin blocks of
TGCT and prostate cancer samples were collected for
tissue microarray (TMA) studies following approvals
obtained from local ethics committees. Written
informed consent was received from participants prior
to inclusion in the study.
SNP array analysis
A standard phenol/chloroform method was used to
extract DNA from cell lines and fresh frozen tissues
with the application of micro- or macro-dissection for
clinical prostate cancer samples. Affymetrix 10 K SNP
arrays (Affymetrix, Santa Clara, CA, USA) were used
according to the manufacturer’s instructions, with stan-
dard quality control steps in the process. Standard
Affymetrix criteria for final call rate and signal inten-
sity were applied to define a successful hybridization.
Signal intensity data from SNP arrays were analysed
using the commercial Partek Genomics Suite (Partek
Incorporated, St Louis, MO, USA) and our in-house
GOLF (V2.2.10) software [13–15]. SNP array data
have been deposited in the Gene Expression Omnibus
database (accession number GSE35216).
Quantitative reverse transcription PCR (Q-RT-PCR)
Total RNA was extracted using Trizol (Invitrogen)
from cell lines and fresh frozen tissues and for
clinical prostate cancer samples micro- or macro-
dissection was used to isolate high-purity tumour
cells. Standard Q-RT-PCR was performed using pre-
designed Taqman gene expression assays targeting
ZDHHC14 (Hs00257233_m1) and the endogenously
expressed GAPDH gene (Hs99999905_m1) (Applied
Biosystems).
Generation of ZDHHC14 antibody
and immunohistochemistry
A polyclonal rabbit antibody targeted to two pep-
tides (H2N-CGLASQDSLHEDSVRG-COOH and
H2N-CPRATPDEAADLERQID-COOH) of human
ZDHHC14 was generated through Eurogentec (Lie`ge,
Belgium) using the First Class program. Immunohis-
tochemistry was performed using the Vector ABC kit
(Vector Laboratories Inc, Burlingame, CA, USA) and
ZDHHC14 antibody, and protein expression scored as
previously described [16].
Next-generation sequencing
The genomic locus of ZDHHC14 (292.42 kb) was
amplified by long-range PCR using the Gene Amp XL
PCR kit (Applied Biosystems) (with primers listed in
Supplementary Table 1). We generated DNA libraries
using the 454 GS FLX Titanium General Library kit
(Roche, Basel, Switzerland) and sequenced them in a
454 Genome Sequencer FLX Instrument (Roche).
Promoter activity and DNA methylation analysis
HEK293 cells were transfected with the promoter-
containing VISA plasmid and the empty VISA plasmid
[17], and luciferase activity was measured using the
One-Glo Luciferase Assay System (Promega, Madison,
WI, USA). Genomic DNA was bisulphite-converted
with the Epi-Tect Bisulfite kit (Qiagen, Venlo, The
Netherlands). Biotin-labeled primers specific for three
regions within the ZDHHC14 promoter region and
one upstream CpG island were used to amplify the
bisulphite-converted DNA (see primer sequences in
Supplementary Table 4). The amplified DNA was used
for pyrosequencing as previously described [18].
Western blotting
Western blotting was performed as previously
described [19] with antibodies against ZDHHC14,
 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 566–577
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
568 M Yeste-Velasco et al
cleaved caspase-7 (Asp198), PARP (Cell Signaling
Technology, Danvers, MA, USA), cyclin D1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and
β-actin (Sigma, St Louis, MO, USA).
Cell viability, proliferation, and apoptosis assays
Cell viability and proliferation were assessed using
the CellTiter 96 AQueous assay (Promega) following
the manufacturer’s instructions. 1500 cells were plated
in each well of a 96-well plate. The following day,
cells were treated with 1 µg/ml tetracycline to induce
ZDHHC14 expression and after 72 h, cell viability
and proliferation were assessed. Cell cycle distribution
was established using a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) as
previously described [19], analysed using FlowJo 8.8.6
software. Apoptosis assays were performed using an
FITC annexin V apoptosis detection kit I (Becton
Dickinson) following the manufacturer’s instructions.
ZDHHC14 transient overexpression and siRNA
knockdown
The 22RV1 cell line was transfected with pcDNA4/TO
plasmid (Invitrogen) containing ZDHHC14 or with the
empty plasmid, using the Amaxa Nucleofector Kit V
(Lonza, Basel, Switzerland), and the HEK293 cell line
with ZDHHC14 WT or mutated S14 construct, using
FuGENE6 (Promega), following the manufacturer’s
instructions. PNT2-C2 cells were transfected with
ZDHHC14 ON-TARGET plus SMARTpool siRNA
(Dharmacon, Lafayette, CO, USA) at 100 nM final
concentration using Oligofectamine (Invitrogen) as
previously described [19].
ZDHHC14 knockout by zinc finger nucleases
PNT2-C2 cells were transfected with ZDHHC14
CompoZrTM Knockout Zinc Finger Nucleases
(CKOZFN23137-1KT, Sigma) using Lipofectamine
and cultured for 3 days. Cells were split and used for
the CEL-I surveyor assay (Transgenomic, Omaha, NE,
USA) to confirm the action of the ZFNs, or seeded for
clonal selection. One hundred clones were expanded
and screened for the presence of ZFN-induced dele-
tions by microsatellite analysis, using a 3730xl DNA
analyser (Applied Biosystems). Positive clones were
sequenced to confirm the deletion.
Colony formation assay
Five hundred cells were plated onto six-well plates and
incubated for 1 week in 5% CO2 at 37 ◦C, washed with
PBS, fixed with 4% paraformaldehyde, and stained
with 0.1% crystal violet solution. The number of visible
colonies was counted.
Xenograft and bioluminescence studies
Male CD1 nude mice (Charles River Limited, UK),
6–8 weeks of age, were used in accordance with
the UK Coordination Committee on Cancer Research
guidelines and Home Office regulations. Mice were
randomly allocated into two groups: one treated with
tetracycline and the other treated with vehicle. One
week after the treatment started, mice were injected
subcutaneously with 2 × 106 293 T-RExTM clone Z14
3 luciferase-tagged cells into their right-side flank
region and with the empty plasmid 4/TO luciferase-
tagged cells into their left flank. Mice were anaes-
thetized and bioluminescence imaging was performed
after intraperitoneal injection of D-luciferin (Caliper
Life Sciences, Hopkinton, MA, USA). The IVIS Vivo-
Vision 100 Imaging System (Xenogen, Alameda, CA,
USA) was used for bioluminescence imaging record-
ing and post-processing. Quantification was performed
using Living Image software 3.2.
Statistics
Statistical tests for data analysis included the chi-
squared test and Student’s t-test, as described in each
section. Statistical analyses were performed using the
Prism 5.0b (GraphPad, La Jolla, CA, USA) statistical
software package. p values of 0.05 or less were
considered significant.
Full experimental procedures are presented in the
Supplementary materials and methods.
Results
Frequent loss of 6q25.3 region affecting ZDHHC14
in TGCTs
To search for new genomic alterations, and in particu-
lar to identify novel putative tumour suppressor genes,
we performed SNP array analysis on 36 TGCT clin-
ical samples, including five with case-matched adja-
cent normal tissues, and three cell lines (833 K, Susa,
and GCT27). The samples without case-matched nor-
mal tissues and cell lines were normalized against the
average of the five normal tissues. We confirmed pre-
viously reported frequent genomic alterations such as
gain on chromosomes 7, 8, 12p, and X, and loss of
4, 5, 11, and 13 [9]. In addition, there were a num-
ber of small regions (<1 mb) with genomic copy
number gains or losses that were mostly detected
in one or two samples, except a loss of a small
genomic region on 6q25.3 that was detected in 48.7%
(19/39) of the cases. In most samples, this loss was
defined by only two contiguous SNPs (Supplementary
Figure 1). In three of five cases with adjacent normal
tissues, this 6q25.3 deletion was observed by directly
comparing the tumour against case-matched normal
tissue (Figure 1), demonstrating somatic genomic alter-
ations. The size of the deletion, based on the two
deleted SNPs and the two adjacent non-deleted SNPs,
can vary from 274 bp (157970668–157970942) to
275 653 bp (157769581–157985234) based on the
GRCh37. This genomic region only contains one
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Figure 1. Frequent loss of the 6q25.3 region affecting ZDHHC14 in TGCTs. Affymetrix 10 K SNP array results of five TGCT samples compared
with case-matched normal tissues. The sub-microscopic deletion of 6q25.3 (indicated by circles) was found in three of these cases. In
cases 74 T and 88T, as in most of the non-matched cases, the deletion was defined by only two contiguous SNPs. In case 87T, the SNP on
the left of the two circled may also be deleted. Each dot represents an SNP and the ZDHHC14 locus is shown within the box. In each case,
the middle line represents a log2 ratio of 0 for SNP signal intensity; the top line a ratio of 1; and the bottom line a ratio of −1.
known gene, ZDHHC14 , which encodes a protein with
an unknown function (Supplementary Figure 1).
ZDHHC14 expression is commonly down-regulated
in TGCTs
After identifying the ZDHHC14 deletion, we inves-
tigated its consequence on expression of this gene.
Firstly, we measured ZDHHC14 mRNA expression
in 40 TGCT clinical samples and three cell lines
and found dramatic underexpression when compared
with three normal testis tissue samples (p < 0.0001)
(Figure 2A). We also studied ZDHHC14 protein
expression by immunohistochemistry. As no commer-
cial antibody was available, we generated an anti-
body against human ZDHHC14 and confirmed its
specificity by western blot and immunocytochemistry
(Supplementary Figures 2A–2C), and demonstrated
its efficiency in staining ZDHHC14 in normal germ
cells (spermatocytes) (Supplementary Figure 2D). We
analysed TMAs comprising 318 cases of TGCTs for
ZDHHC14 expression and found that ZDHHC14 was
significantly underexpressed compared with morpho-
logically normal seminiferous tubules adjacent to the
cancers (p = 0.0013). ZDHHC14 levels were divided
into three categories: negative, weakly positive, and
strongly positive. All normal testicular tissue samples
were positive, whereas 21.4% of TGCT samples were
negative (Figures 2B and 2C).
ZDHHC14 expression is down-regulated in prostate
cancer
Since TSGs often are involved in the genesis
of more than one type of malignancy, and the
Oncomine database revealed that ZDHHC14 mRNA
was also down-regulated in lymphoma, liposar-
coma, brain, kidney, lung, and colorectal cancers
(data from the Oncomine database http://www.
oncomine.org/resource/login.html), we investigated
ZDHHC14 expression in prostate cancer. We detected
a clear down-regulation of ZDHHC14 mRNA in 38
cancer samples compared with 21 benign prostatic
hyperplasia (BPH) samples (p < 0.0001). ZDHHC14
mRNA was also underexpressed in the prostate cancer
cell lines PC-3, DU-145, 22RV1, LNCaP, and VCaP
(Figure 3A). We next studied ZDHHC14 protein
expression by immunohistochemistry, analysing 483
prostate cancer clinical samples, 73 with adjacent BPH
or normal prostate glands, made into 11 TMAs and
50 BPH samples from non-cancer cases constructed in
one TMA. Within the prostate gland, basal cells were
strongly stained. The luminal epithelial cells in all
normal and BPH samples were also positively stained.
However, only 53% (256/483) of the cancer samples
were positively stained (p < 0.001; chi-squared test)
(Figures 3B and 3C). This result taken with those
from the Oncomine database suggests that ZDHHC14
down-regulation is a feature of many human cancers.
We re-examined our published SNP array data [15,16]
for genomic loss of the ZDHHC14 region, which was
found in five cases from 71 clinical samples and six
cell lines.
ZDHHC14 mutations are uncommon and promoter
methylation is unaffected in TGCTs and prostate
cancer
The presence of mutations within the coding region
would provide additional insight into the mechanism
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Figure 2. ZDHHC14 expression is commonly down-regulated in TGCTs. (A) Significant ZDHHC14 mRNA underexpression in 40 primary
tumours (black bars) was detected, compared with three normal testis tissues (white bars). ZDHHC14 down-regulation was also found in
three TGCT cell lines (GCT27, Susa, and 833K). Means and SEMs were calculated for both groups and a two-tailed Student’s t-test was
applied. The sample codes, in the same order as the graph, are T115, T113, T108, 9T, 10T, 18T, 29T, 33T, 58T, 66T, 75T, 86T, 90T, 93T, 94T,
105T, 108T, RH4, RH6, RH9, RH11, RH14, RH15, RH16, RH17, RH24, RH26, RH27, RH29, RH36, RH37, RH39, RH42, RH43, RH44, RH45,
RH46, RH48, 1532/99, 2805/97, 3425/98, 6534/98, 7942/99, 833K, GCT27 and Susa. (B) ZDHHC14 protein expression was down-regulated
in TGCTs compared with non-malignant testis tissue as detected by immunohistochemistry. ZDHHC14 expression levels were divided into
three categories: negative, weakly positive, and strongly positive. This table shows the number of cases and percentages in each group
and category, which were compared using a two-tailed chi-squared test. (C) Representative images of the three categories of ZDHHC14
expression from TGCTs (200× original magnification) and normal testicular tissues (400× original magnification).
of ZDHHC14 inactivation. We therefore sequenced
the nine exons of ZDHHC14 in three TGCT clin-
ical samples (29 T, 86 T, and 94 T) and three cell
lines (833 K, GCT27, and Susa). We found one
heterozygous missense point mutation in exon 4 and
a 99-base pair deletion of the beginning of exon 4,
corresponding to the DHHC domain, in Susa cells
(Table 1). Encouraged by these results, we performed
next-generation sequencing (NGS) of the entire
ZDHHC14 gene and the 5′ upstream region containing
the putative promoter, in ten DNA pools containing
31 TGCT and two prostate cancer clinical samples
and five prostate cancer cell lines (22RV1, DU-145,
PC-3, LNCaP, and VCaP) (Supplementary Table 2).
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Figure 3. ZDHHC14 expression is commonly down-regulated in prostate cancer. (A) ZDHHC14 mRNA is significantly underexpressed in 38
prostate cancer (PCa) samples (black bars) compared with 21 BPH samples (white bars). Five prostate cancer cell lines (PC-3, DU-145,
22RV1, LNCaP, and VCaP) also showed down-regulation. Means and SEMs were calculated for both groups and a two-tailed Student’s
t-test was applied. (B) Down-regulated ZDHHC14 protein expression was detected by immunohistochemical analysis in prostate cancer
samples compared with BPHs and adjacent normal prostate tissues. This table shows the number of cases and percentages in each group
and category, and the two-tailed chi-squared test result (p < 0.001). (C) Images corresponding to representative examples from each
expression level category in each group (200× original magnification).
The coverage of the ZDHHC14 gene in the pools
ranged from 78% to 92%, with the average depth for
each sample from 11 to 145 reads. The quality (Phred
score) was above 30 in all the samples (Supplementary
Figure 3 and Supplementary Table 3). We detected
two missense point mutations in exons 3 and 9 in
the prostate cancer cell line pool, none of them
annotated as SNPs in the 1000 Genomes database
(http://www.1000genomes.org/home). The missense
point mutations in exons 3 and 9 were confirmed in
the LNCaP cell line by Sanger sequencing (Table 1).
Although the missense mutations were scored as
damaging using SIFT mutation prediction software
(http://sift.jcvi.org/), the finding of mutations solely
in cell lines indicates that ZDHHC14 mutation may
not greatly contribute to its inactivation in those two
tumour types. We also assessed promoter methylation
status as a possible cause leading to ZDHHC14 down-
regulation. The promoter region was unmethylated
in both non-malignant and malignant prostate and
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Table 1. List of the mutations found in the ZDHHC14 gene
Sample Method Gene location Genomic position Type of mutation Size (bp) NT change AA change
TGCT Susa cell line Exon sequencing Exon 4 158,049,459 Point mutation 1 T> C L215S
TGCT Susa cell line Exon sequencing Exon 4 158,049,380–479 Deletion 99 NA NA
LNCaP PCa cell line NGS Exon 3 158,014,155 Point mutation 1 G>A C181Y
LNCaP PCa cell line NGS Exon 9 158,093,804 Point mutation 1 G>A A373Y
TGCT= testicular germ cell tumour; PCa= prostate cancer; NGS= next-generation sequencing; NA= not applicable.
A B
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Figure 4. Decreased cell viability by activation of caspase-dependent apoptosis in 293 T-REx ZDHHC14-overexpressing clones. (A) Using
293 T-REx cells, we generated three tetracycline-inducible clones stably overexpressing ZDHHC14 (Z14 1, 2, and 3) and an empty plasmid-
expressing clone (4/TO), to be used as a control. Treatment with tetracycline (Tetra) for 72 h induced different ZDHHC14 overexpression
levels in the three clones. A representative example of three independent experiments is shown. (B) Decreased cell viability, directly
proportional to ZDHHC14 overexpression, was detected in all three clones by MTS assay after 72 h of tetracycline treatment. (C) Apoptosis
was quantified by FACS analysis of annexin V-positive cells (AV+) and (D) subG1 cells after 72 h tetracycline treatment. Means and SEMs
of triplicates were calculated and a two-tailed Student’s t-test was applied. (E) Cleavage of the classic apoptotic markers caspase-7 (top
row) and PARP (middle row) in ZDHHC14-overexpressing HEK293 T-REx cells. Western blotting was performed after 72 h tetracycline
treatment. A representative example of three independent experiments is shown.
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testicular clinical samples (Supplementary Figure 4),
ruling out promoter hypermethylation as the cause
for ZDHHC14 underexpression in prostate cancer and
TGCTs.
ZDHHC14 activates a classic caspase-dependent
apoptotic pathway
To confirm the tumour suppressor role of ZDHHC14
and also to attempt to elucidate its cellular function,
we generated a tetracycline-inducible ZDHHC14-
overexpressing stable 293 T-REx cell line and isolated
three clones that overexpressed ZDHHC14 at different
levels (Figure 4A). Overexpression of ZDHHC14
decreased cell number in all three clones, with this
decrease being directly proportional to ZDHHC14
expression levels (Figure 4B). This result was due
to ZDHHC14 overexpression inducing apoptosis, as
determined by quantification of annexin V-positive
cells and sub-G1 apoptotic cells by FACS analysis
(Figures 4C and 4D), which were again proportional
to ZDHHC14 levels. We also found cleavage of
caspase-7 and PARP (Figure 4E), showing that the
classic caspase-dependent pathway was involved. We
then performed transient overexpression of ZDHHC14
in 22RV1 prostate cancer cells, which led to an
increase in sub-G1 apoptotic cells together with the
cleavage of caspase-7 and PARP (Figure 5). This
result confirms the involvement of ZDHHC14 in
inducing apoptosis and supports its role as a tumour
suppressor in prostate cancer.
In order to determine if ZDHHC14’s apoptotic
function was due to its palmitoyltransferase activity,
we transiently transfected HEK293 cells with either
wild-type ZDHHC14 or a mutated catalytic DHHC
domain construct. We detected that the decrease in
cell viability and increase in apoptosis were lower
in the mutant construct transfected cells than in cells
transfected with the wild type, although the mutated
construct still had lower viability levels than the
empty vector transfected cells, probably due to the
inherent toxicity of overexpressing a protein (Sup-
plementary Figure 5). These data demonstrate the
involvement of the catalytic DHHC domain in inducing
apoptosis.
ZDHHC14 heterozygous deletion increases colony
formation
To further confirm the tumour suppressor role of
ZDHHC14, we attempted its knockdown by siRNA
in several cell lines, obtaining efficient mRNA knock-
down, but no decrease at protein level. This was a
consequence of the slow turnover rate of ZDHHC14
protein, as determined by persistent detection of
ZDHHC14 expression after 6 days’ treatment with the
protein synthesis inhibitor cycloheximide (Supplemen-
tary Figure 6). shRNA stable knockdown was also
attempted but without efficient knockdown even at
the RNA level. Finally, we used zinc finger nucleases
(ZFNs) to knock out ZDHHC14 in immortalized
prostate epithelial PNT2-C2 cells. After screening 100
clones derived from cells transfected with ZDHHC14
ZFNs, we found a clone with an 11 bp deletion in one
of the two alleles. This deletion generates a stop codon
immediately after it (Figure 6A). This heterozygous
deletion decreased ZDHHC14 protein expression
compared with a mock transfected clone and with the
parental cells (Figure 6B and Supplementary Figure
2). Colony formation assays showed both more and
larger colonies in the ZDHHC14 heterozygous deleted
cells than in parental and mock transfected cells
(Figures 6C and 6D), further confirming the tumour
suppressor role of ZDHHC14 .
Increased ZDHHC14 expression suppresses
xenograft tumour initiation
To assess the role of ZDHHC14 in tumour growth in
vivo, we employed xenograft experiments using the
293 T-REx cells described above. We chose clone 3,
with the highest ZDHHC14 levels, and the empty
plasmid clone as a control. We randomly allocated
ten mice into two groups and initiated the treatment
by administrating tetracycline in drinking water, or
vehicle for the control group. After 7 days, all mice
A B DC
Figure 5. Transient overexpression of ZDHHC14 in the prostate cancer cell line 22RV1 induces caspase-dependent apoptosis. 22RV1
prostate cancer cells were transiently transfected with ZDHHC14 (Z14) or empty plasmid (4/TO) and checked for ZDHHC14 mRNA
expression after 24 h by Q-RT-PCR (A), and for protein expression after 48 h by western blotting (B). (C) Induced apoptosis by ZDHHC14
overexpression shown as an increase of subG1 population by FACS analysis 48 h after transfection. Means and SEMs of triplicates were
calculated and a two-tailed Student’s t-test was applied. (D) Cleavage of caspase-7 (top row) and PARP (middle row) detected 48 h after
transfection by western blotting. A representative example is shown. Z14 = ZDHHC14 transfected; 4/TO = empty plasmid transfected cells.
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Figure 6. Heterozygous deletion of ZDHHC14 generated by zinc finger nucleases in the immortalized prostate epithelial cell line PNT2-C2
increases colony formation ability. (A) Sequence alignment of wild-type ZDHHC14 (Sbjct) and heterozygous deleted clone (Query) showing
an 11 bp deletion in exon 1. The T before and the GA after the deletion generate a stop codon (TGA). (B) Western blot showing decreased
ZDHHC14 expression in the heterozygous deleted clone (Z14 ZFN) compared with mock transfected clone and the parental cells. (C) Colony
formation assay showing increased colony formation, in both numbers and sizes, in the heterozygous deleted clone compared with a mock
transfected clone and parental cells. (D) Quantification of colony numbers expressed as means and SEMs of triplicates; a two-tailed paired
Student’s t-test was applied.
A B
C
Figure 7. Increased ZDHHC14 expression suppresses xenograft tumour initiation. (A) Growth of xenograft tumours measured by volume
from 293 T-REx ZDHHC14 transfected cells (Z14 3) injected into the right flank (red line) and empty plasmid transfected cells (4/TO)
injected into the left flank (blue line) of five nude mice treated with tetracycline. (B) Tumour growth curves measured by quantification
of the bioluminescence that emanated from the luciferase-tagged 293 T-REx ZDHHC14 or 4/TO cells. (C) Representative bioluminescence
imaging of a tetracycline-treated mouse at different dates post-inoculation, showing tumour growth only in the left flank, where empty
plasmid transfected cells were injected. Bioluminescence is presented as a pseudo-colour scale: red, highest photon flux; blue, lowest
photon flux.
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in each group were injected subcutaneously with the
ZDHHC14 plasmid-containing cells into the right flank
and with the empty plasmid cells into the left flank,
using each mouse as its own control. The presence of
tumour cells and tumour growth was checked period-
ically, showing that tetracycline-dependent ZDHHC14
overexpression completely blocked tumour initiation,
since none of these mice developed tumours in the
right flank (Figure 7). In contrast, the same cells in
the vehicle-treated mice grew to form a tumour in all
cases (data not shown). As expected, cells transfected
with empty plasmid developed tumours in all the mice
in the tetracycline group (Figure 7) and in the vehicle
group (data not shown). These results demonstrate that
ZDHHC14 has a tumour suppressor role in vivo.
Discussion
Tumour suppressor genes play critical roles in pre-
venting tumourigenesis and are frequently inactivated
during tumour development and progression. Deletion
of 6q has been reported frequently in human tumours
and one or more TSGs located within this region
have been proposed [20–22]. Using SNP microarrays
on TGCTs, we detected a frequent small deletion
in chromosome region 6q25.3 containing only one
known gene, ZDHHC14 . This region is also deleted
in prostate cancer samples, although at a much
lower frequency [15,16]. These data suggest that
ZDHHC14 may be a putative TSG. This hypothesis
has been further supported by the dramatic ZDHHC14
down-regulation found in TGCT and prostate cancer.
Currently, there are only three studies on ZDHHC14,
which paradoxically reported a putative oncogenic role
for ZDHHC14 based on its up-regulation in gastric
cancer [23], diffuse large B-cell and mantle cell lym-
phomas [24], and acute biphenotypic leukaemia and
subsets of acute myeloid leukaemia [25]. Based on the
different substrate specificities of DHHC proteins [26],
it is plausible that ZDHHC14 has several substrates
and, depending on the cellular type and context, can
regulate different pathways. Therefore, ZDHHC14
might play oncogenic roles in some cell types and
tumour suppressor roles in others. However, in publicly
accessible databases, there is much evidence to support
the tumour suppressor role of ZDHHC14 . ZDHHC14
is underexpressed in many human cancers, including
lymphoma, liposarcoma, and brain, kidney, lung and
colorectal cancers (data from the Oncomine database
http://www.oncomine.org/resource/login.html). In
addition, since the cancer genome sequencing efforts
started, 36 mutations affecting the ZDHHC14 cod-
ing region have been described and ZDHHC14
gene mutation recurrence has been found in colon
adenocarcinoma (4/257 samples), lung adenocarcinoma
(5/305 samples) (data from the COSMIC database
http://www.sanger.ac.uk/genetics/CGP/cosmic/ and the
International Cancer Genome Consortium database
http://dcc.icgc.org/), lung squamous cell carcinoma
(3/178 samples) [27], uterine corpus endometrioid
carcinoma (4/240 samples) [28], colorectal cancer
(2/72 samples) [29], and skin cutaneous melanoma
(4/228 samples) (data from The Cancer Genome Atlas
database http://cancergenome.nih.gov/). All these
data support ZDHHC14 as a putative TSG that is
commonly affected in many types of human cancer.
The inactivation of a TSG can be achieved by
its complete switching off (two-hit mechanism),
by haploinsufficiency, or even by its subtle down-
regulation (quasi-insufficiency) [30]. In this study,
nearly all ZDHHC14 deletions were heterozygous and
in most cases, ZDHHC14 was down-regulated but
not completely lost. In addition, the limited number
of missense mutations found means that in most of
the cases, the other allele may remain functional.
These results suggest that haploinsufficiency or
quasi-insufficiency is enough to inactivate the tumour
suppressor role of ZDHHC14. This mechanism is also
supported by our functional studies, which showed a
ZDHHC14 dose response effect in suppressing cell
growth and activating apoptosis, and an increased
colony formation ability by heterozygous knockout.
Regarding the mechanism leading to ZDHHC14
down-regulation, ZDHHC14 deletion has a pivotal role
in TGCTs. However, some samples without the dele-
tion expressed lower ZDHHC14 levels than samples
with the deletion, indicating that other mechanisms
may be involved. In both TGCTs and prostate can-
cer, our data showed that ZDHHC14 mutation and
DNA methylation may not contribute much to its
inactivation. Therefore, other transcriptional or post-
transcriptional mechanisms should be the main cause
of ZDHHC14 down-regulation in prostate cancer cases
without genomic deletions.
Our final approach to confirm the tumour suppressor
role of ZDHHC14 was to perform functional studies.
While its cellular function has not been studied,
ZDHHC14 belongs to the DHHC palmitoyltransferase
family. It was recently discovered that the main
function of DHHC proteins is protein palmitoylation, a
reversible post-translational lipid modification that reg-
ulates membrane tethering and localization/function
of key proteins in cell signalling and membrane
trafficking [26,31]. Deregulation of certain palmi-
toyltransferases has been reported in several diseases
including neurological disorders and cancer [32].
Although protein palmitoylation plays an important
role in cellular function, it is poorly understood [31,33]
and DHHC proteins remain understudied. There are
23 DHHC proteins in humans, of which a small
number, including DHHC9 [34,35], HIP14/DHHC17
[36], Aph2/DHHC16 [37,38], and DHHC2 [39–41],
have reported roles in cancer. We showed in vitro that
ZDHHC14 heterozygous deletion increases colony
formation and that overexpression suppresses cell
growth by promoting apoptosis through the classic
caspase-dependent pathway, which also explains
why ZDHHC14 overexpression in xenograft tumours
 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2014; 232: 566–577
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
576 M Yeste-Velasco et al
totally blocks tumour initiation. Our functional analy-
sis using a DHHC domain mutated construct showed
that palmitoylation is partially responsible for the
pro-apoptotic role of ZDHHC14, which is further
supported by the deletion found in exon 4 in Susa
cells affecting the DHHC domain. There are also
several examples linking palmitoylation and apoptosis
[37,38,42–45]. However, further studies are required
to fully dissect the molecular mechanism linking
ZDHHC14 and caspase-dependent apoptosis.
In summary, we have demonstrated that ZDHHC14 ,
a palmitoyltransferase DHHC family gene, is com-
monly inactivated in human cancers and that it may
exert a tumour suppressor role through the induction of
apoptosis. This is the first study showing the involve-
ment of ZDHHC14 in a specific pathway, the clas-
sic caspase-dependent apoptotic pathway. These data,
together with our in vivo data showing the block-
ing of tumour xenograft initiation, demonstrate that
ZDHHC14 is a bona fide tumour suppressor gene.
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